Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model
Cancer Medicine · 2024
DOI: 10.1002/cam4.70316 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yuqi Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Disease Progression, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Introduction
There is an urgent clinical need to accurately predict the risk for disease progression in post‐treatment NSCLC patients, yet current ctDNA mutation profiling approaches are limited by low sensitivity. We represent a non‐invasive liquid biopsy assay utilizing cfDNA neomer profiling for predicting disease progression in 44 inoperable localized NSCLC patients.
Methods
A total of 97 plasma samples were collected at various time points during or post‐treatments (TP1: 39, TP2: 33, TP3: 25). cfDNA neomer profiling, generated based on target sequencing data, was used to fit survival support vector machine models for each time point. Leave‐one‐out cross‐validation (LOOCV) was performed to evaluate the models' predictive performances.
Results
Our cfDNA neomer profiling assay showed excellent performance in detecting patients with a high risk for disease progression. At TP1, the high‐risk patients detected by our model showed an increased risk of 3.62 times (hazard ratio [HR] = 3.62, p = 0.0026) for disease progression, compared to 3.91 times (HR = 3.91, p = 0.0022) and 4.00 times (HR = 4.00, p = 0.019) for TP2 and TP3. These neomer profiling determined HRs were higher than the ctDNA mutation‐based results (HR = 2.08, p = 0.074; HR = 1.49, p  = 0.61) at TP1 and TP3. At TP1, the predictive model reached 40% sensitivity at 92.9% specificity, outperforming the mutation‐based method (40% sensitivity at 78.6% specificity), while the combination results reached a higher sensitivity (60%). Finally, the longitudinal analysis showed that the combination of neomer and ctDNA mutation‐based results could predict disease progression with an excellent sensitivity of 88.9% at 80% specificity.
Conclusion
In conclusion, we developed a cfDNA neomer profiling assay for predicting disease progression in inoperable NSCLC patients. This assay showed increased predicting power during and post‐treatment compared to the ctDNA mutation‐based method, thus illustrating a great clinical potential to guide treatment decisions in inoperable NSCLC patients. Trial Registration ClinicalTrials.gov: NCT04014465
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Wanxiangfu Tang, Nan Bi
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wu, Y., Li, C., Yang, Y., Zhang, T., Wang, J., Tang, W., Li, N., Bao, H., Wang, X., & Bi, N. (2024). Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model. Cancer Medicine. https://doi.org/10.1002/cam4.70316
Vancouver
Wu Y, Li C, Yang Y, Zhang T, Wang J, Tang W, et al. Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model. Cancer Medicine. 2024. doi:10.1002/cam4.70316
BibTeX
@article{Wu2024,
author = {Wu, Yuqi and Li, Canjun and Yang, Yin and Zhang, Tao and Wang, Jianyang and Tang, Wanxiangfu and Li, Ningyou and Bao, Hua and Wang, Xin and Bi, Nan},
title = {Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70316}
}
EUVIMED